US Anti Nuclear Antibody Testing Market

ID: MRFR/LS/17220-HCR
100 Pages
Satyendra Maurya
Last Updated: April 06, 2026
US Anti-Nuclear Antibody Testing Market Research Report By Type (immunofluorescence, enzymelinked, immunosorbent assay, others), By Application (Rheumatoid arthritis, Systemic lupus erythematosus, Polymyositis, Scleroderma, Sjögren's syndrome, others) and By End User (Hospitals and clinics, research laboratories, others) - Growth & Industry Forecast 2025 To 2035
US Anti Nuclear Antibody Testing Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)6.49%
2024 Market Size$ 390.6 Million
2025 Market Size$ 415.95 Million
2035 Market Size$ 780 Million
Key Players
Thermo Fisher Scientific
Abbott Laboratories
Roche Diagnostics
Siemens Healthineers
Bio-Rad Laboratories
Ortho Clinical Diagnostics
Trends
  • Technological Advancements
  • Rising Autoimmune Disease Incidence
  • Focus on Personalized Medicine
Opportunities
  • Growing Geriatric Population
  • Advancements in Diagnostic Technologies
  • Integration of Telemedicine in Healthcare
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Test Type (USD Million)
      1. 4.1.1 Fluorescent Anti-Nuclear Antibody Test
      2. 4.1.2 Enzyme-Linked Immunosorbent Assay
      3. 4.1.3 Latex Agglutination Test
      4. 4.1.4 Western Blot Test
    2. 4.2 Pharmaceutical, BY End User (USD Million)
      1. 4.2.1 Hospitals
      2. 4.2.2 Diagnostic Laboratories
      3. 4.2.3 Research Institutes
    3. 4.3 Pharmaceutical, BY Indication (USD Million)
      1. 4.3.1 Systemic Lupus Erythematosus
      2. 4.3.2 Rheumatoid Arthritis
      3. 4.3.3 Sjgren's Syndrome
      4. 4.3.4 Mixed Connective Tissue Disease
    4. 4.4 Pharmaceutical, BY Component (USD Million)
      1. 4.4.1 Reagents
      2. 4.4.2 Kits
      3. 4.4.3 Control Materials
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Thermo Fisher Scientific (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Abbott Laboratories (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche Diagnostics (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Siemens Healthineers (DE)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Bio-Rad Laboratories (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Ortho Clinical Diagnostics (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Fujirebio (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Euroimmun (DE)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Hoffmann-La Roche (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TEST TYPE
    3. 6.3 US MARKET ANALYSIS BY END USER
    4. 6.4 US MARKET ANALYSIS BY INDICATION
    5. 6.5 US MARKET ANALYSIS BY COMPONENT
    6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
    9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    12. 6.12 PHARMACEUTICAL, BY TEST TYPE, 2024 (% SHARE)
    13. 6.13 PHARMACEUTICAL, BY TEST TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
    15. 6.15 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
    16. 6.16 PHARMACEUTICAL, BY INDICATION, 2024 (% SHARE)
    17. 6.17 PHARMACEUTICAL, BY INDICATION, 2024 TO 2035 (USD Million)
    18. 6.18 PHARMACEUTICAL, BY COMPONENT, 2024 (% SHARE)
    19. 6.19 PHARMACEUTICAL, BY COMPONENT, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY END USER, 2025-2035 (USD Million)
      3. 7.2.3 BY INDICATION, 2025-2035 (USD Million)
      4. 7.2.4 BY COMPONENT, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Anti Nuclear Antibody Testing Market Segmentation

US Anti Nuclear Antibody Testing Market By Test Type (USD Million, 2025-2035)

  • Fluorescent Anti-Nuclear Antibody Test
  • Enzyme-Linked Immunosorbent Assay
  • Latex Agglutination Test
  • Western Blot Test

US Anti Nuclear Antibody Testing Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes

US Anti Nuclear Antibody Testing Market By Indication (USD Million, 2025-2035)

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Sjgren's Syndrome
  • Mixed Connective Tissue Disease

US Anti Nuclear Antibody Testing Market By Component (USD Million, 2025-2035)

  • Reagents
  • Kits
  • Control Materials

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.